Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021-Reference-Cited by-同舟云学术

Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021

Published:2021-06-24 Issue:25 Volume:26 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Mateo-Urdiales Alberto¹²^ORCID,Spila Alegiani Stefania³,Fabiani Massimo²,Pezzotti Patrizio²,Filia Antonietta²,Massari Marco³,Riccardo Flavia²,Tallon Marco⁴,Proietti Valeria⁵,Del Manso Martina¹²,Puopolo Maria⁶,Spuri Matteo²,Morciano Cristina⁷,D’Ancona Fortunato (Paolo)²,Da Cas Roberto³,Battilomo Serena⁵,Bella Antonino²,Menniti-Ippolito Francesca³, ,

Affiliation:

1. European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

2. Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy

3. National Centre for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy

4. Department of Informatics, Istituto Superiore di Sanità, Rome, Italy

5. DG-SISS, Ministero della Salute, Rome, Italy

6. Department of Neuroscience, Istituto Superiore di Sanità, Rome, Italy

7. Research Coordination and Support Service, Istituto Superiore di Sanità, Rome, Italy

Abstract

To assess the real-world impact of vaccines on COVID-19 related outcomes, we analysed data from over 7 million recipients of at least one COVID-19 vaccine dose in Italy. Taking 0–14 days post-first dose as reference, the SARS-CoV-2 infection risk subsequently decreased, reaching a reduction by 78% (incidence rate ratios (IRR): 0.22; 95% CI: 0.21–0.24) 43–49 days post-first dose. Similarly, hospitalisation and death risks decreased, with 89% (IRR: 0.11; 95% CI: 0.09–0.15) and 93% (IRR: 0.07; 95% CI: 0.04–0.11) reductions 36–42 days post-first dose. Our results support ongoing vaccination campaigns.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference13 articles.

1. Agenzia Italiana del Farmaco (AIFA). Vaccini COVID-19. Rome: AIFA. [COVID-19 Vaccines]. [Accessed 19 May 2021]. Available from: https://www.aifa.gov.it/vaccini-covid-19

2. Ministero della Salute. Piano strategico per la vaccinazione anti-SARS-CoV-2/COVID-19. [Strategic plan for SARS-CoV-2 / COVID-19 vaccination]. Rome: Ministero della Salute; 2020. Italian. Available from: https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2021&codLeg=78657&parte=1&serie=null

3. Epidemiological characteristics of COVID-19 cases and estimates of the reproductive numbers 1 month into the epidemic, Italy, 28 January to 31 March 2020.;Riccardo;Euro Surveill,2020

4. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.;Polack;N Engl J Med,2020

5. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.;Baden;N Engl J Med,2021

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk Factors for Long COVID in Older Adults;Biomedicines;2023-11-08

2. SARS-CoV-2 Infection, Vaccination and Risk of Death in People with An Oncological Disease in Northeast Italy;Journal of Personalized Medicine;2023-08-29

3. Impact of COVID-19 vaccination on COVID-19 hospital admissions in England during 2021: an observational study;Journal of the Royal Society of Medicine;2023-02-24

4. Risk of Infection and Duration of Protection after the Booster Dose of the Anti-SARS-CoV-2 Vaccine BNT162b2 among Healthcare Workers in a Large Teaching Hospital in Italy: Results of an Observational Study;Vaccines;2022-12-22

5. Effectiveness of Pfizer/BioNTech and Sinopharm COVID-19 vaccines in reducing hospital admissions in prince Hamza hospital, Jordan;Frontiers in Public Health;2022-09-21